WO1995009862A1 - Water-soluble retinoids - Google Patents
Water-soluble retinoids Download PDFInfo
- Publication number
- WO1995009862A1 WO1995009862A1 PCT/EP1994/003187 EP9403187W WO9509862A1 WO 1995009862 A1 WO1995009862 A1 WO 1995009862A1 EP 9403187 W EP9403187 W EP 9403187W WO 9509862 A1 WO9509862 A1 WO 9509862A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- preparation
- retinoic acid
- sugar
- Prior art date
Links
- 0 CC1(C)C(C=CC(C)=C=C=CC(C)=CC(OCC(C(C2O)O)O*C2O)=O)=C(C)CCC1 Chemical compound CC1(C)C(C=CC(C)=C=C=CC(C)=CC(OCC(C(C2O)O)O*C2O)=O)=C(C)CCC1 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
- C07H13/06—Fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
Definitions
- the present invention relates to water-soluble novel sugar retinoids , and to their preparation and the use thereof as medicaments and in the cosmetic sector.
- Retinoic acid derivatives are commonly used in the field of dermatology. Thus keratinising epithelial tissue can be converted by retinoic acid or derivatives thereof into tissue of normally differentiated cells. The retinoids exert a protective action against chemically, photochemically or virally induced carcinogenesis and assume protective functions in cell division. Retinoic acid itself is water-insoluble and is therefore usually converted into a water-soluble form for ease of handling.
- Aromatic retinoids having a saccharide or aminosaccharide radical and which are suitable dermatalogical agents for use in pharmaceuticals and cosmetics, are disclosed in US-A-4565 863. For toxicological reasons, such aromatic retinoids are sought to be avoided.
- the present invention provides retinoic acid esters of formula (I)
- X is a sugar residue attached at an oxygen atom, i.e. a mono-, di- or oligosaccharide, provided that X is not a glucose- or galactose sugar residue attached at the oxygen atom in the respective 1 -positions of the glucose- or galactose sugar residues.
- the double bonds in the retinoic acid radical may be in cis- or trans-configuration, the all-trans-form being preferred.
- Oligosaccharides containing more than two sugar units may suitably be in particular compounds such as streptomycin, neuraminic acid, fucose, ⁇ , ⁇ , ⁇ -cyclodextrin, raffinose or short-chain degradation products of amylose or cellulose.
- the sugar radical is preferably a mono- or disaccharide which is derived from ribose, arabinose, xylose, glucose, mannose, galactose, lactose, saccharose, trehalose, cellobiose, maltose, fructose or derivatives thereof.
- Suitable derivatives of these sugars include: desoxy sugars; the lactones of the corresponding sugar acids such as gluconic acid ⁇ -lactone which in turn may be esterified by C 1 -C alkyl; uronic acids; amino sugars having an unsubstituted amino group, typically glucosamine, fructosamine, galactosamine, or having a C r C 6 alkyl- or Cj-C ⁇ acetyl-substituted amino group, e.g.
- aminoethyl- glucosides aminoethyl-2-deoxy-2-aminoglucoside, N-acetylaminoglucoside
- sugars in which the OH groups are substituted by one or more than one C j ⁇ alkoxy group e.g. methyl or ethyl glucose, substitution by Cx ⁇ alkylene bridges also being possible
- keto- sugar acids such as ascorbic acid
- sugars in which the OH groups are mono- or polyacetyl- ated, typically glucose acetate or 2,3,4-tri-O-acetylglucose
- sugars carrying several different substituents e.g. neuraminic acid.
- sugars are glucose, galactose, mannose or derivatives thereof.
- the aforementioned sugar radicals may also be in the form of racemates or any mixtures of the (L)- and (D)-configuration as well as in the form of the pure (L)- or (D)-isomers.
- the natural (D)-configuration is preferred.
- Rj, R 2 , R 3 and R 4 are OH, C ⁇ -C4alkoxy, C r C 3 -COO-, or two of these radicals taken together are a O-C j -Q-O-alkylene bridge;
- novel compounds of formula (I) are prepared by a) converting retinoic acid into a reactive derivative, and b) adding a mono-, di- or oligosaccharide.
- the retinoic acid can be converted into a reactive derivative such as an imidazolide, a mixed anhydride or an acid chloride.
- the acid chloride is preferred.
- This conversion is preferably carried out with chloroenamine or dimethylchlorofo ⁇ na- midinium chloride, using any solvent which is inert to the chlorinating reagent and which at least partially dissolves the retinoic acid, conveniently selected from among ethers, amides, aromatic hydrochlorides, esters, halogenated hydrocarbons, nitriles and sulfoxides.
- solvents are methylene chloride, dimethyl formamide, toluene, ethyl acetate, acetonitrile, dimethyl sulfoxide and hexane.
- the sugar can be used in already derivatised form or it is derivatised after the linkage to the retinoic acid or after the sulfation. It is preferred to use sugars in which the OH groups that are not to be esterified are provided with protective groups so as to achieve a selective linkage of the sugar to the acid chloride.
- the protective groups used for this purpose are normally diol protective groups such as isopropylidene, benzylidene or ethylene protective groups, and they are prepared in known manner. After the linkage of the sugar to the retinoic acid, these groups can be removed again in known manner.
- the reaction of the sugar with the retinoic acid derivative preferably takes place under the same conditions as are used for the derivatisation of the retinoic acid, and a base such as pyridine can be added to promote the reaction.
- the compounds of formula (I) can be used for the cosmetic and pharmacological treatment of the eyes or skin, for example for tautening and rejuvenating the skin, for the treatment of acne, psoriasis, neoplasms, dermatoses, as well as for preventive treatment to provide protection from ultraviolet radiation.
- the compounds of formula (I) are formulated with conventional carriers.
- Topical application is preferred. Such application comprises treating the skin with an effective amount of the compound of formula (I).
- a pharmaceutical or cosmetic composition containing a compound of formula (I) may be administered or applied in the form of tablets, granules, capsules, dragees, ointments, creams, tinctures, lotions, solutions, suspensions, hydrogels, liposomes or foam sprays.
- Suitable carriers include mixtures of different emulsifiers, dispersants, stabilisers, perfume oils, antioxidants, thickeners, diluents, humectants, fillers, salts for changing the osmotic pressure, and buffers.
- Typical examples of such carriers are gelatin, lactose, starch, fatty acid salts, talcum, gum arabic, polyalkylene glycols and other non-toxic excipients.
- the concentration of active ingredient may be from 0.01 to 5 % by weight, depending on the dosage form.
- the protected ⁇ -D-galactopyranose of Example 1 is replaced with the following sugars (unprotected or in suitably protected form): ribose, arabinose, xylose, lactose, saccharose, trehalose, cellobiose, maltose, fructose, neuraminic acid, fucose, ⁇ , ⁇ , ⁇ -cyclodextrin or raffinose, to give water-soluble derivatives of retinoic acid which can be used for the cosmetic and pharmacological treatment of the eyes or skin.
- sugars unprotected or in suitably protected form
- Example 2 In accordance with the general procedure described in Example 1, reaction of all-trans-retinoic acid (1) and l,2:5,6-di-O-isopropylidene-D-glucose, followed by subsequent removal of the protective groups, gives a compound of formula (5)
- Example 3 In accordance with the general procedure described in Example 1, reaction of all-trans-retinoic acid (1) and l,2:4,5-di-O-isopropylidene-D-fructose, followed by subsequent removal of the protective groups, gives a compound of formula (6)
- Example 4 In accordance with the general procedure described in Example 1, reaction of all-trans-retinoic acid (1) and 2,3:5,6-di-0-isopropylidene- ⁇ -D-mannofuranose, followed by sub a (7)
- a cream of the following composition is prepared
- Example 6 The procedure of Example 5 is repeated, but using a compound of formula (4) of Example 1 as monosaccharide.
- Example 7 The procedure of Example 5 is repeated, but using a compound of formula (6) of Example 3 as monosaccharide.
- Example 8 The procedure of Example 5 is repeated, but using a compound of formula (7) of Example 4 as monosaccharide.
- a transparent hydrogel of the following composition is prepared: 0.1 % of the compound of formula (5)
- Example 2 20.0 % of 1,2-propylene glycol 20.0 % of isopropanol 2.0 % of acrylic acid polymer 3.0 % of triethanolamine perfume oils as required, and demineralised water to make up 100 %
- the acrylic acid polymer and water are dispersed and the dispersion is neutralised with triethanolamine.
- the monosaccharide retinoic acid ester (5) is dissolved in a mixture of isopropanol and propylene glycol and the solution is mixed with other components to a gel.
- Example 10 The procedure of Example 9 is repeated, but using a compound of formula (4) of Example 1 as monosaccharide.
- Example 11 The procedure of Example 9 is repeated, but using a compound of formula (6) of Example 3 as monosaccharide.
- Example 12 The procedure of Example 9 is repeated, but using a compound of formula (7) of Example 4 as monosaccharide.
- a foam spray of the following composition is prepared: 0.03 % of the compound of formula (5) of Example 2 5.00 % of 1,2-propylene glycol 1.70 % of cetyl alcohol 1.00 % of paraffin oil, viscous 2.00 % of isopropyl myristate 2.40 % of Cetomacrogol 1000® 1.50 % of sorbitan monostearate 0.18 % methyl parabene 0.10 % propyl parabene 0.10 % of Chemoderm 314® perfume oils as required, and demineralised water to make up 100 %
- Cetyl alcohol, paraffin oil, isopropyl myristate, Cetomacrogol 1000® and sorbitan stearate are fused and the methyl- and propyl parabene, dissolved in propylene glycol, and hot water are added at 75°C and the mixture is homogenised. After cooling to 40°C, the monosaccharide retinoic acid ester (5), Chemoderm 314® and optional perfume oils are added. 20 ml of the mixture are filled into an aluminium lacquer-coated container which is closed with a valve and filled with propellant gas under pressure.
- Example 14 The procedure of Example 13 is repeated, but using a compound of formula (4) of Example 1 as monosaccharide.
- Example 15 The procedure of Example 13 is repeated, but using a compound of formula (6) of Example 3 as monosaccharide.
- Example 16 The procedure of Example 13 is repeated, but using a compound of formula (7) of Example 4 as monosaccharide.
- Example 17 In accordance with the test method of L.H. & A.M.Kligman [The effect on rhino mouse skin of agents which influence keratinisation and exfoliation, J.Invest.Dermatol.,73, 354-358 (1979)], rhino mice are treated for 3 weeks, twice a day, each time with a) a 0,05% solution of the compound of formula (5), namely glucose retinate, or with b) a 0.025% solution of retinic acid, the solvent in each case being ethano polyethylene glycol (90:10, v:v).
- the two test compounds provide a comparable normalisation of the skin structure (reduction of the u riculi).
- Retinic acid causes, as a side effect, a significant reddening of the skin, which undesirable effect is not observed with the compound of formula (5).
- Example 18 In order to detect any possible teratogenic effect, the compound of formula (5) is tested, using retinic acid as a comparison, in a rat embryo culture using the method of L.Cicurel & B.P.Schmid [Postimplantation embryo culture for the assessment of the teratogenic potential and potency of compounds, Experientia 44, 833-40 (1988)]. Whereas retinic acid induces malformations, even at a concentration of 0.3 ⁇ g/ml, no malformations occur at up to 10 ⁇ g/ml with the compound of formula (5).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU78096/94A AU687098B2 (en) | 1993-10-06 | 1994-09-24 | Water-soluble retinoids |
BR9407758A BR9407758A (en) | 1993-10-06 | 1994-09-24 | Water-soluble retinoids |
JP7510586A JPH09503499A (en) | 1993-10-06 | 1994-09-24 | Water soluble retinoid |
KR1019960701755A KR960704904A (en) | 1993-10-06 | 1994-09-24 | Water-soluble retinoids |
US08/624,379 US5780443A (en) | 1993-10-06 | 1994-09-24 | Water-soluble retinoids |
EP94928806A EP0722451A1 (en) | 1993-10-06 | 1994-09-24 | Water-soluble retinoids |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9320610.0 | 1993-10-06 | ||
GB9320610A GB2282596B (en) | 1993-10-06 | 1993-10-06 | Water-soluble retinoids |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995009862A1 true WO1995009862A1 (en) | 1995-04-13 |
Family
ID=10743103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1994/003187 WO1995009862A1 (en) | 1993-10-06 | 1994-09-24 | Water-soluble retinoids |
Country Status (13)
Country | Link |
---|---|
US (1) | US5780443A (en) |
EP (1) | EP0722451A1 (en) |
JP (1) | JPH09503499A (en) |
KR (1) | KR960704904A (en) |
AU (1) | AU687098B2 (en) |
BR (1) | BR9407758A (en) |
CZ (1) | CZ100896A3 (en) |
GB (1) | GB2282596B (en) |
HR (1) | HRP940646A2 (en) |
HU (1) | HUT74456A (en) |
IL (1) | IL111152A (en) |
WO (1) | WO1995009862A1 (en) |
ZA (1) | ZA947775B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996010403A1 (en) * | 1994-09-30 | 1996-04-11 | Alcon Laboratories, Inc. | Use of retinoid glycosides in topical pharmaceutical compositions |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2813789B1 (en) * | 2000-09-11 | 2003-05-02 | Ind E Com De Cosmeticos Natura | NOVEL COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING AN ASSOCIATION OF VITAMIN C AND / OR WITH A FUCOSE COMPONENT AND USE OF SAID COSMETIC OR PHARMACY ASSOCIATION |
US20040136938A1 (en) * | 2000-09-11 | 2004-07-15 | Robert Ladislas | Composition of vitamin c and/or vitamin a |
US20040021483A1 (en) * | 2001-09-28 | 2004-02-05 | Brian Boles | Functional pathway configuration at a system/IC interface |
US20060201531A1 (en) * | 2001-12-04 | 2006-09-14 | Brown Dale G | Methods for coating dental devices with sialagogue emulsions |
JP5285201B2 (en) * | 2002-09-25 | 2013-09-11 | 株式会社ナノエッグ | Retinoic acid nanocapsule |
ITMI20022745A1 (en) * | 2002-12-23 | 2004-06-24 | Coimex Scrl United Companies | MIXED ESTERS OF HYALURONIC ACID FOR CYTOSTATIC AND MANUFACTURING ACTIVITIES AND PROCEDURE FOR THEIR PRODUCTION. |
JP4535238B2 (en) * | 2004-03-17 | 2010-09-01 | 国立大学法人 香川大学 | Retinoic acid ester of psicose and method for producing the same |
US20160038593A1 (en) * | 2004-12-22 | 2016-02-11 | Nitto Denko Corporation | Drug carrier and drug carrier kit for inhibiting fibrosis |
US20060237021A1 (en) * | 2005-04-21 | 2006-10-26 | Guay Gordon G | Methods and devices for rejuvenating skin |
US20110081410A1 (en) * | 2005-06-28 | 2011-04-07 | St. Marianna University, School Ofmedicine | Therapeutic agent for local inflammation |
KR101002795B1 (en) | 2008-09-19 | 2010-12-21 | (주)더페이스샵 | Novel Retinyl Ascorbate Compounds and Preparation Method thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2598420A1 (en) * | 1986-05-06 | 1987-11-13 | Oreal | NOVEL RETINOIC ESTERS OF ANTIBIOTICS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME |
EP0315540A1 (en) * | 1987-11-04 | 1989-05-10 | L'oreal | Retinoic esters of macrolides, method for their preparation and pharmaceutical and cosmetic compositions containing them |
EP0356154A2 (en) * | 1988-08-26 | 1990-02-28 | Sawai Pharmaceutical Co., Ltd. | Trehalose derivatives |
EP0388308A1 (en) * | 1989-03-16 | 1990-09-19 | L'oreal | Retinoic esters of D-desosamine, method for their preparation and their use in human or veterinary medicine and in cosmetics |
WO1990014093A1 (en) * | 1989-05-22 | 1990-11-29 | Iowa State University Research Foundation, Inc. | Water-soluble vitamin a preparations for application to the skin |
WO1993021195A1 (en) * | 1992-04-21 | 1993-10-28 | Ciba-Geigy Ag | Water-soluble retinoids |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4457918A (en) * | 1982-05-12 | 1984-07-03 | The General Hospital Corporation | Glycosides of vitamins A, E and K |
CH661516A5 (en) * | 1983-12-08 | 1987-07-31 | Hoffmann La Roche | PHENYLNONATETRAENOYL SUGAR DERIVATIVES. |
-
1993
- 1993-10-06 GB GB9320610A patent/GB2282596B/en not_active Expired - Fee Related
-
1994
- 1994-09-24 BR BR9407758A patent/BR9407758A/en not_active Application Discontinuation
- 1994-09-24 HU HU9600884A patent/HUT74456A/en unknown
- 1994-09-24 EP EP94928806A patent/EP0722451A1/en not_active Withdrawn
- 1994-09-24 CZ CZ961008A patent/CZ100896A3/en unknown
- 1994-09-24 JP JP7510586A patent/JPH09503499A/en active Pending
- 1994-09-24 KR KR1019960701755A patent/KR960704904A/en not_active Application Discontinuation
- 1994-09-24 AU AU78096/94A patent/AU687098B2/en not_active Ceased
- 1994-09-24 WO PCT/EP1994/003187 patent/WO1995009862A1/en not_active Application Discontinuation
- 1994-09-24 US US08/624,379 patent/US5780443A/en not_active Expired - Fee Related
- 1994-10-04 IL IL11115294A patent/IL111152A/en not_active IP Right Cessation
- 1994-10-05 ZA ZA947775A patent/ZA947775B/en unknown
- 1994-10-05 HR HR9320610.0A patent/HRP940646A2/en not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2598420A1 (en) * | 1986-05-06 | 1987-11-13 | Oreal | NOVEL RETINOIC ESTERS OF ANTIBIOTICS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME |
EP0315540A1 (en) * | 1987-11-04 | 1989-05-10 | L'oreal | Retinoic esters of macrolides, method for their preparation and pharmaceutical and cosmetic compositions containing them |
EP0356154A2 (en) * | 1988-08-26 | 1990-02-28 | Sawai Pharmaceutical Co., Ltd. | Trehalose derivatives |
EP0388308A1 (en) * | 1989-03-16 | 1990-09-19 | L'oreal | Retinoic esters of D-desosamine, method for their preparation and their use in human or veterinary medicine and in cosmetics |
WO1990014093A1 (en) * | 1989-05-22 | 1990-11-29 | Iowa State University Research Foundation, Inc. | Water-soluble vitamin a preparations for application to the skin |
WO1993021195A1 (en) * | 1992-04-21 | 1993-10-28 | Ciba-Geigy Ag | Water-soluble retinoids |
Non-Patent Citations (1)
Title |
---|
A.B. BARUA ET AL.: "All-trans Retinoyl Beta-Glucose: Chemical Synthesis, Growth-Promoting Activity and Metabolism in the Rat", INTERNAT. J. VIT. NUTR. RES., vol. 61, 1991, pages 258 - 263 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996010403A1 (en) * | 1994-09-30 | 1996-04-11 | Alcon Laboratories, Inc. | Use of retinoid glycosides in topical pharmaceutical compositions |
Also Published As
Publication number | Publication date |
---|---|
AU687098B2 (en) | 1998-02-19 |
CZ100896A3 (en) | 1996-10-16 |
GB2282596B (en) | 1998-04-15 |
GB9320610D0 (en) | 1993-11-24 |
BR9407758A (en) | 1997-03-04 |
US5780443A (en) | 1998-07-14 |
JPH09503499A (en) | 1997-04-08 |
HUT74456A (en) | 1996-12-30 |
HU9600884D0 (en) | 1996-06-28 |
AU7809694A (en) | 1995-05-01 |
HRP940646A2 (en) | 1997-04-30 |
EP0722451A1 (en) | 1996-07-24 |
KR960704904A (en) | 1996-10-09 |
GB2282596A (en) | 1995-04-12 |
ZA947775B (en) | 1995-05-17 |
IL111152A (en) | 2001-03-19 |
IL111152A0 (en) | 1994-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU687098B2 (en) | Water-soluble retinoids | |
US20100069311A1 (en) | Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders | |
Ossowski et al. | Synthesis of a glucoheptaose and a glucooctaose that elicit phytoalexin accumulation in soybean. | |
CA1234107A (en) | Retinoid acylates of sugars and amino sugars | |
IE50463B1 (en) | Sugar derivatives | |
US5674852A (en) | Water-soluble retinoids | |
JP4856809B2 (en) | Topical skin preparation | |
JP2007084484A (en) | External preparation for skin | |
JP3340928B2 (en) | Melanin production inhibitor and whitening cosmetic | |
JPS6289608A (en) | External preparation for skin | |
JPH02268192A (en) | Retinoic acid ester of d-desosamine, its production, medicine for human or veterinary use and cosmetic composite | |
JPH1017462A (en) | Melanin formation-suppressing agent and beautifying cosmetic | |
JPH10175820A (en) | Suppressant for melanogenesis and beautifying and whitening cosmetic | |
JPS61207317A (en) | External agent for skin | |
US5004733A (en) | Esters of the etretinic type or related to macrolidic and lincosamidic antibiotics and pharmaceutical and cosmetic compositions containing said esters | |
CA3239173A1 (en) | Photodynamic therapy and diagnosis | |
JP3754653B2 (en) | Topical skin preparation | |
JPH01193289A (en) | Diaromatic ester of macrolide and lincosamide antibiotics, production thereof and drug/cosmetics | |
JPH09301990A (en) | Sesamol glucide and preparation for external use for skin | |
JPS61210011A (en) | External preparation for skin | |
JPH07291989A (en) | Hydroquinonehydroxyalkyl ether glycoside | |
JPH06340621A (en) | Indole compound | |
MXPA06004822A (en) | Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CZ FI HU JP KR NZ PL SI SK US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1994928806 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08624379 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1996-1008 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1994928806 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1996-1008 Country of ref document: CZ |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994928806 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: PV1996-1008 Country of ref document: CZ |